AM0001 / Eli Lilly, Ligand - LARVOL DELTA

Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double Blind, Randomized, Placebo Controlled Study (AHA 2024) - "Adverse events were evenly distributed.ConclusionsAnatomically directed delivery of AMG0001 is well-tolerated and significantly improved time to complete healing in people with moderate CLTI and concomitant neuroischemic ulcers. HGF gene transfer may offer a promising alternative for the treatment of patients with CLTI."

Clinical • Gene therapy • Cardiovascular • Gene Therapies • Peripheral Arterial Disease • HGF

"Our fellow @Mohamedsami0001 present our poster on gain/amp1q in AL amyloidosis and it’s prognostic significance #USCAP2022" (@monakashim1)

Amyloidosis • SKAP2

Annotation of chemotaxis gene clusters and proteins involved in chemotaxis of Bacillus subtilis strain MB378 capable of biodecolorizing different dyes. (PubMed, Environ Sci Pollut Res Int) - "Methyl-accepting proteins (involved in chemotaxis regulation) belonged to pfam00672, pfam00072, and pfam00015 protein families...Considering results of present study, it can be speculated that test compounds triggered chemotactic genes, which made these compounds bioavailable to the bacterium. Hence, the bacterium recognized and approached these compounds and facilitated biodegradation and detoxification of these compounds."

Journal

First report of stem rust, caused by Puccinia graminis, and crown rust, caused by Puccinia coronata var. avenae f. sp. avenae, on tall fescue (Festuca arundinacea) in Georgia, USA. (PubMed, Plant Dis) - "GAM00013162), was discarded as an earlier record of P. coronata var...avenae f. sp. avenae on tall fescue in Georgia, USA."

Journal • Infectious Disease

AGILITY: Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia (clinicaltrials.gov) - P3; N=46; Terminated; Sponsor: AnGes; Trial primary completion date: Feb 2019 ➔ Mar 2017

Trial primary completion date • Biosimilar • Gene Therapies • Reperfusion Injury

A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia (clinicaltrials.gov) - P=N/A; N=9; Completed; Sponsor: AnGes USA, Inc.; Active, not recruiting ➔ Completed; Trial completion date: Jul 2019 ➔ Jan 2020; Trial primary completion date: Jul 2019 ➔ Jan 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date

".@Mohamedsami0001 @DrIlyas123 @AbsiaJabbar @dalialuko @DrAnasYounes @dr_uche_bee @MrAdedaps @AnnaLeeMDMPH @SLeonMD @Doc_Pat1028 @BossnationDNilo @andreahuiaustin @DouglasJamesMD1 @Ivez @darakass @MichaelOBrienMD @NYKK_MD @SaraHarvy @TastyKeish @DrLenaG @theotherdsw" (@brooklyn_grows)

Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: AnGes USA, Inc.

Clinical • New P2 trial

Comparative analysis of protein profiles of prognosis-associated proteins and KIT-related proteins in gastrointestinal stromal tumour (ESMO Asia 2019) - "Background: Gastrointestinal stromal tumor (GIST) is a type of mesenchymal tumor and has KIT mutations in 80–90% of the cases. HSP 90-beta is currently considered as a therapeutic target for HSP 90 inhibitors against imatinib-resistant GIST. Our data suggests that the differentiation and cell growth of GIST may be enhanced by the identified proteins, which are in turn induced by KIT. We believe that our established protein profile data will help in improving the understanding of malignant behaviors in GIST.Legal entity responsible for the study: Juntendo University."

PD(L)-1 Biomarker

A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia (clinicaltrials.gov) - P=N/A; N=9; Active, not recruiting; Sponsor: AnGes USA, Inc.; Trial completion date: Feb 2019 ➔ Jul 2019; Trial primary completion date: Feb 2019 ➔ Jul 2019

Clinical • Trial completion date • Trial primary completion date

A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia (clinicaltrials.gov) - P=N/A; N=9; Active, not recruiting; Sponsor: AnGes USA, Inc.; Enrolling by invitation ➔ Active, not recruiting

Clinical • Enrollment closed